Table 2.

Multivariate analyses of inflammatory indexes as predictors of platinum-free interval.

	PFI (< 6 months)		PFI (< 12 months)
	OR (95% CI)*	p*	OR (95% CI)*	p*
Overall population
NLR
< 3	1.00	0.006	1.00	0.036
≥ 3	2.52 (1.30–4.87)		2.05 (1.05–4.01)
SII
< 730	1.00	0.413	1.00	0.786
≥ 730	0.74 (0.36–1.53)		0.91 (0.45–1.84)
CT group
NLR
< 3	1.00	0.004	1.00	0.027
≥ 3	2.77 (1.38–5.56)		2.27 (1.10–4.70)
SII
< 730	1.00	0.498	1.00	0.663
≥ 730	0.76 (0.35–1.67)		0.84 (0.39–1.82)
CTB group
NLR
< 3	1.00	0.538	1.00	0.774
≥ 3	0.47 (0.04–5.15)		0.75 (0.11–5.25)
SII
< 730	1.00	0.696	1.00	0.599
≥ 730	1.65 (0.13–20.56)		1.78 (0.21–15.14)

CI, confidence interval; CT, chemotherapy; CTB, chemotherapy with bevacizumab; NLR, neutrophil-to-lymphocyte ratio; OR, odd ratio; PFI, platinum-free interval; SII, systemic immune-inflammation index.

*Adjusted for ECOG performance status, histology, stage and ascites.